Obesity and prediabetes. Treatment using GLP-1 receptor agonists

Background. Glucagon-like peptide 1 (GLP-1) receptor agonists receptor agonists have been available for the treatment of type 2 diabetes mellitus in Germany since 2007. One improvement over existing therapies was the induction of weight loss of approximately 1-4 kg in the majority of patients. Obesity and prediabetes treatment. The underlying mechanism is the physiologic function of GLP-1 to regulate appetite and food intake in humans. These therapeutic effects are also present in non-diabetic individuals, thus providing a new approach to treating obesity. In addition, effective treatment of prediabetes and hyperglycemia is achieved by regulation of islet hormone levels (insulin and glucagon). However, GLP-1 receptor agonist treatment does not have a disease modifying effect to induce long-term normalization of glucose metabolism even after discontinuation of active therapy. Therefore it is necessary to combine GLP-1 receptor agonists with established therapies for obesity and prediabetes, primarily lifestyle intervention, in order to improve the long-term results of obesity and prediabetes treatment.